MedTrace Logo

Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

NCT05113693 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2023-06-09

No results posted yet for this study

Summary

Objective

\- Evaluation of the pharmacokinetic properties and safety of CKD-393 0.25/50/750 mg oral administration in healthy adults under fed condition.

Conditions

Interventions

DRUG

CKD-393

QD, PO

DRUG

CKD-501, D759, H053

QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Min Gul Kim, M.D, Ph.D. · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
54 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-25
Primary Completion
2021-12-06
Completion
2021-12-10

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05113693 on ClinicalTrials.gov